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ABSTRACT 
 
Introduction: HuŶtiŶgtoŶ͛s disease (HD) is an inherited progressive neurodegenerative condition. 
Predictive direct mutation testing of at-risk individuals has been available since 1993.  
 
Methods: The UK HuŶtiŶgtoŶ͛s Prediction Consortium collected anonymised data on all UK 
predictive tests, annually, from 1993-2014. Using the HD prevalence figure of 12.3 per 100 000, we 
determined the cumulative uptake of predictive testing in the at-risk population.  
 
Results: From 1993-2014, 9407 predictive tests were performed in 23 UK centres. Where gender 
was recorded, 4077 participants were male (44.3%) and 5122 were female (55.7%). The median age 
of participants was 37.7 years. The most common reason for predictive testing was to reduce 
uncertainty (70.5%). Of 8441 predictive tests on individuals at 50% apriori risk, 4629 (54.8%) were 
reported as gene negative, 3790 (44.9%) were gene positive with 22 (0.3%) uninterpretable. The 
cumulative uptake of predictive testing in the 50% at-risk UK population from 1994-2014 was 
estimated at 17.4% (95% CI: 16.9-18.0%). 
 
Discussion: Here we present the largest study ever conducted on predictive testing in HD. Our 
findings indicate the vast majority of individuals at-risk of HD (>80%) have not undergone predictive 
testing. Future therapies in HD will likely target pre-symptomatic individuals, therefore 
characterising the at-risk population whose gene-status is unknown is of significant public health 
value.  
 
Keywords: HuŶtiŶgtoŶ͛s disease, Predictive Testing, Pre-symptomatic Testing, Prevalence  
 
(Maximum 200 words for abstract); currently 214.   
INTRODUCTION 
HuŶtiŶgtoŶ͛s disease (HD) is a slowly progressive and ultimately fatal autosomal dominant inherited 
neurodegenerative disorder characterised by development of abnormalities in movement, cognitive 
decline and behavioural disturbances (1). The disease is caused by an expanded CAG repeat in the 
first exon of the HTT gene which encodes an abnormal polyglutamine expansion in the huntingtin 
protein resulting in selective neuronal degeneration (2).  
 
In addition to the symptomatic population with an expanded allele, there are several-fold more 
individuals at risk of developing the condition (3). Predictive testing for HD first became available in 
1986 with linkage analysis (4, 5) and was superseded by direct mutation analysis in 1993. The advent 
of optional pre-symptomatic testing in HD has profoundly influenced the lives of this at-risk 
population and has become a paradigm for predictive testing for genetic disorders as a broader 
clinical entity. Individuals at-risk are able to establish, with near certainty, whether they will develop 
HD or not. This clearly has implications on an individual level (personal wellbeing, relationships, 
family planning, employment and finances) (6) and on a societal level (targeted healthcare and social 
service provision). Given the significance of a positive result and the current paucity of disease 
modifying medical interventions, guidelines recommend a comprehensive programme consisting of 
genetic counseling and generally restrict access to those aged 18 and over (7). 
 
Cumulative uptake of predictive testing has classically been expressed as the number of predictive 
tests performed as a proportion of those estimated to be at 50% risk in the population (8). This 
methodology is problematic as it ignores the fact that, as new cases of HD are diagnosed, the 
number of individuals known to be at-risk of HD in a given population (the denominator in the 
equation) increases over time; as such, previous studies have overestimated the cumulative uptake 
of predictive tests. In the absence of a national, comprehensive HD population registry with detailed 
information on family pedigrees, establishing the at-risk population is difficult. To overcome this 
problem, Tassicker et al (9) have proposed a method to determine the cumulative at-risk population 
over time which accounts for the changing at-risk population and disease duration. This method has 
been applied by smaller, centrally organised centres in Victoria, Australia (9) and Northern Ireland 
(10) and has provided measures of cumulative uptake of predictive testing in HD that are more 
consistent with observations made by HD Counsellors and Clinical Geneticists (9).  
 
Here, using the UK HuŶtiŶgtoŶ͛s Prediction CoŶsortiuŵ͛s (UK HPC) data  from 1993 – 2014, we 
update our previous study (8) and report on the largest study ever conducted on the experience of 
predictive testing for HD.  
 
 
  
METHODS 
Data Recording 
The UK HPC was launched in 1989 to systematically collect anonymised data on all completed pre-
symptomatic tests for HD in the UK and to provide a forum for the evolving discussion of issues 
pertaining to predictive testing (8). Forms were completed by nominated participants at each centre 
and were entered into a central database by the Consortium Coordinator. All 23 centres in the UK 
offering predictive testing have participated contemporaneously from the outset giving near 
complete coverage of data.  
 
Data recorded included the testing centre, gender, age of testee, prior genetic risk, details of the 
type of genetic test and final result. From 1993-2006, the test results were characterised as being 
normal/unaffected (<36 CAG repeat length on largest allele) or abnormal/affected ;≥ 36 repeat 
length on the largest allele). From 2007, centres also began to report on intermediate alleles (28-35 
CAG repeat length on the largest allele) and reduced penetrance alleles (36-39 CAG repeat length on 
the largest allele). In later years, information on the ethnicity of testees, maternal/paternal origin of 
mutation and reasons for predictive testing were also recorded.  
 
Descriptive analysis was performed on all predictive tests performed from 1993 - 2014. The 
calculation of the cumulative uptake of predictive testing was determined from predictive tests 
performed from 1994-2014 which represents 21 complete years of testing.  
 
Calculations for Cumulative Uptake of Predictive Testing (1994-2014) 
The inclusion criteria for the cumulative uptake analysis were as follows: 
(1) Age 18 or over. The rationale for this is that those under 18 are not eligible for predictive 
testingi although some tests have been carried out for exceptional circumstances related to 
planning health and social care interventions. This will be the subject of a future publication. 
(2) Family history of confirmed HuŶtiŶgtoŶ͛s disease and an a priori risk of 50% at conception 
(first degree relative affected or a carrier).   
(3) Completed testing protocol with the final result available.  
 
The exclusion criteria for the cumulative uptake were as follows:  
(1) Prenatal testing for HuŶtiŶgtoŶ͛s disease.  
 
Data on predictive tests were available for 23 testing centres for the period 1993 to 2014. Because 
predictive testing only became available towards the end of 1993, this year was excluded from the 
analysis. Within each year, tests were included for those who were 18 years and over, and who were 
identified as being at 50% risk. There were 483 centre-level data collection periods in total (i.e. 21 
years multiplied by 23 centres). Ten centres did not report data for one or more years, which 
resulted in 26 of the 483 (5.4%) of the centre-level data collection periods having missing data. We 
assumed missing data were missing at random ;͚MAR͛Ϳ and used multiple imputation based on 
predictive mean matching to impute plausible values based on year and centre  (11). 
 
The cumulative uptake of predictive testing over the study period was determined using the formula 
described by Tassicker et al (9): 
 
Uptake (%) =  (T/D) x 100 
 
Where: 
T  = Cumulative number of predictive tests performed on eligible participants ;≥ 18 years old) 
                 with a prior risk of 50% over the study period.  
 
 
D  = Cumulative number of eligible individuals at 50% risk of HD over the study period  
= P +   
 
P  = Number of individuals at 50% risk who are eligible for testing at the start of the 
                study (prevalence in the adult population x 4.2).  
 
The cumulative number of individuals at 50% risk (P) of HD is the sum of the eligible individuals at 
50% risk at the start of the study and those individuals who become eligible over the course of the 
study. In order to calculate reliably the population at 50% risk, accurate estimates of the prevalence 
of HD in the general population are required. This is itself a contentious issue (see Discussion). In the 
present study, the prevalence figure of 12.3 per 100 000 in adult population was used to calculate 
the cumulative uptake of predictive testing over the study period. 
 
Classically, the ratio of the number of symptomatic individuals (prevalence) to individuals at 50% risk 
of developing HD in a population has been described as being, on theoretical grounds, 1:5 (3). 
Tassicker et al (9) revised this to a ratio of 1:4.2 based on their own empirical data from multiple 
source ascertainment of at-risk individuals in Victoria, Australia; this revised ratio is similar to the 
empirical data from Northern Ireland (10). A ratio of 1:4.2 was used to calculate the cumulative 
uptake as it is based on empirical evidence. Discrepancies in the estimated prevalence of HD and the 
ratio of symptomatic individuals to individuals at 50% risk in the research literature were accounted 
for by performing a sensitivity analysis to calculate multiple uptake figures based on several different 
parameter estimates. 
 
Disease duration, from onset of symptoms to death, was taken as being 18.8 years based on the 
average of the reported median disease duration in two large cohort studies (15, 16). Mid-year 
population estimates for those 18 and over were obtained for the UK for each year in the period 
1994 to 2014 (17).  
 
Statistical Analysis  
Descriptive analysis was carried out using SPSS Statistics software (Version 22). For the main results, 
point estimates and 95% confidence intervals are reported. In order to calculate confidence intervals 
observed counts were assumed Poisson distributed. Imputation of missing data was via predictive 
mean matching based on centre and year.  The imputation of missing data was carried out using the 
mice package in R (Version 3.2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Demographic information and apriori risk  
Between 1993 and 2014, 9407 predictive tests for HuŶtiŶgtoŶ͛s disease were performed in 23 
centres in the United Kingdom. The demographic information and apriori risk of participants are 
summarised in Table 1.  
 
There were slightly more females than males who undertook predictive testing (54.4% vs 43.3%). 
Data on gender was not available for 208 individuals (2.2%). The median age for undergoing 
predictive testing was 37 years (interquartile range: 29-47 years).  
 
The majority of participants undergoing predictive testing had an apriori risk of 50% (89.7%). For a 
minority of participants (3.3%), the apriori risk could not be determined because of one of the 
following reasons: the risk estimate was missing from the dataset; expressed as a figure determined 
from a life-risk table; described in qualitative terms rather than an apriori risk; or the risk was 
determined to be very low and the predictive testing protocol was being carried out as part of the 
pre-implantation genetic diagnosis protocol as they had a gene-positive partner.  
 
 
Predictive Testing by Year  
Predictive testing by direct mutation testing became available part-way through 1993. In the later 
years of the study the response rate from participating centres was not complete, therefore, 
minimal missing data was imputed using the standard procedure described in the Methods. In the 
initial years of predictive testing (1994-1998), the mean number of tests performed annually on 
those ≥18 years old with a 50% apriori risk, after imputation of missing data, was 535 (SD 2.9). From 
1999-2014, the corresponding figure had fallen to 362 (SD 1.9).  
 
 
Reasons for Testing 
Patient-reported reasons for undergoing testing were not recorded uniformly for all centres or 
consistently throughout the study. Reasons for predictive testing were recorded for 4743 (50.4%) 
participants and we can report on the number of responses recorded for the five most common 
reasons for predictive testing (summarized in Table 2). Participants were allowed to cite multiple 
reasons for predictive testing and this is reflected in the results. The most common patient-reported 
reasons for undertaking predictive testing were to ͞reduce uncertainty ͞ (70.5% of responders) and 
for ͞future-planning͟ (57.7%). Other reasons included ͞to provide information to relatives͟ (38.3%), 
͞reproductive decision making͟ (23.0%) and the ͞hope for future treatments͟ (9.6%). Rarer reasons 
for predictive testing included: testing as part of the assisted reproduction protocols, 
insurance/mortgage purposes, ͞curiosity,͟ patient-reported symptoms, the absence of prior genetic 
confirmation in families with a clinical diagnosis of HD and to plan social care in individuals with pre-
existing learning or physical disabilities.  
 
Test Outcomes 
9372 tests (99.6%) were performed by direct mutation analysis characterizing the CAG repeat 
length. 27 tests (0.3%) were performed by linkage analysis and 8 participants had both tests (0.1%). 
The majority of linkage tests (93%) were carried out before 1994.  
 
Of the 8441 predictive tests performed on individuals with an apriori risk of 50% from 1993-2014, 
4629 (54.8%) were reported as gene negative (CAG repeat length <36) whilst 3790 (44.9%) were 
reported as gene positive (CAG repeat length ≥36Ϳ. 22 results (0.3%) were missing or 
uninterpretable.  
 
It is important to note that intermediate and reduced penetrance alleles were not reported on 
uniformly and consistently from the outset of the study so the raw figures from 1993-2014 cannot 
be used to quantify reliably the frequency of these alleles in the 50% at-risk population. To assess 
this more accurately, a subgroup analysis was performed on the predictive tests performed from 
2010 onwards, by which point the vast majority of centres had begun to report on intermediate and 
reduced penetrance alleles. From 2010-2014, 77 results were reported as intermediate alleles (4.2%) 
and 82 results were reported as reduced penetrance alleles (4.5%). The outcomes of predictive 
testing are summarised in Table 2.  
 
Cumulative Uptake of Predictive Testing  
From 1994-2014, after imputation of minimal missing data,  8113 predictive tests performed on 
participants aged ≥ 18 and with an apriori risk of 50% were recorded in the database. After 
imputation of minimal missing data, an estimated 8382 predictive tests were performed in the same 
group. Figure 1 illustrates the selection criteria for cases for the analysis of the cumulative uptake of 
predictive testing.  
 
Cumulative uptake of predictive testing over the study period (1993-2014) was calculated using the 
Tassicker formula described in the Methods: 
 
 
Uptake (%)  =  
 
  = 17.4%  
 
  
The calculated cumulative uptake of predictive testing in the eligible population at 50% risk of HD 
from 1993-2014 is 17.4% (95% CI 16.9%, 18.0%). This is based on a prevalence figure in adults of 
12.3 per 100 000 and on the ratio of symptomatic HD cases to population at 50% risk of developing 
HD as being 1:4.2. Figure 2 illustrates the cumulative uptake of predictive testing in the 50% at-risk 
population from 1994-2014 over time.  Table 3 shows the cumulative uptake estimates assuming 
alternative prevalence figures and ratios of symptomatic individuals: 50% at risk individuals.  
 
DISCUSSION 
Main Findings  
The data presented here represents the largest study ever conducted on the uptake of predictive 
testing for HuŶtiŶgtoŶ͛s disease in a single population. Over a 22 year period from 1993-2014, 9407 
predictive tests were recorded and the estimated cumulative uptake of predictive testing for the UK 
population at 50% risk of developing Huntington͛s disease from 1994-2014 was 17.4% (95% CI 
16.9%, 18.0%). 
 
Several previous studies of predictive testing in HuŶtiŶgtoŶ͛s disease have overestimated the 
cumulative uptake of tests by the at-risk population by not correcting for the fact that the at-risk 
population is dynamic and increases over the study period. Our group previously reported a similar 
cumulative uptake figure of 18% after only four complete years of predictive testing (1993-1997) (8); 
this represents an overestimation of the uptake of predictive testing in 1997 as the former study 
used a lower prevalence of 7.5 per 100 000 and does not correct for the increasing at-risk population 
over time.  
 
Table 4 summarises the key features of other studies of the uptake of predictive testing in 
Huntington͛s disease. Our estimated uptake of 17.4% is comparable to figures of 12.3-14.6% in 
Northern Ireland (10) and 15.4% in Victoria, Australia (9) where the Tassicker formula (9) was 
applied. In the remaining studies, the reported uptake of predictive testing varies from 5% - 44.7%, 
however, it is imperative to note that there are major methodological differences in the approaches 
to these uptake calculations that invalidates a direct comparison with our findings. For instance, in 
Slovenia, where an uptake figure of 44.7% was reported, the authors included tests performed on 
those at apriori risks <50% and expressed uptake as the fraction of tests performed on those 
identified at-risk from their registries and medical records rather than the estimated at-risk 
population (18); using this method, any incomplete ascertainment of at-risk individuals will lead to 
an overestimate of cumulative uptake. The sources of variation in uptake measurements are 
summarised in Table 5.  
 
A low uptake of predictive testing in HuŶtiŶgtoŶ͛s disease has been consistently reported in several 
different populations. Broadly, this may be explained by factors related to autonomous decision 
making by individuals or by issues related to accessing services. The individual choice to undertake 
predictive testing may be affected by the absence of disease modifying treatments, anxiety about an 
abnormal result, the financial implications of an abnormal result, personal experiences caring for 
relatives with HuŶtiŶgtoŶ͛s disease or perceived stigma associated with the condition. Barriers to 
accessing predictive testing may include the travel requirements required to access counselling and 
testing services, the stress of travelling, opportunity costs of missed work or time with family 
members, the inflexibility of the testing process and difficulty in accessing support (19). 
Furthermore, many at-risk individuals may not necessarily be aware that a relative has been 
diagnosed with the condition and, therefore, will not be able to access testing services; this may be 
more true of individuals with an apriori risk of <50%. In the United Kingdom, 23 centres offer 
predictive testing so the geographic barriers to testing may be less influential in determining the 
uptake rate.  
 
Of the 9199 predictive tests where the gender was recorded, 55.7% of the participants were female. 
This is consistent with the majority of studies of uptake in predictive testing where there is a slight 
female preponderance among those tested (18, 20-26). Several theories have been proposed to 
explain this finding; it may be that females are more likely to address questions relevant to 
reproductive planning and may feel better equipped to cope with an abnormal result (27).  
 
The median age for participants who underwent predictive testing was 37. This is slightly higher than 
Greece (21), Slovenia (18) and France (20) but slightly younger than the figures of 39.3 and 41 
reported in Canada (24) and Victoria (25), respectively. An interesting finding was that 6.2% of tests 
were performed on participants aged >60 years old. As life expectancies increase, there may be a 
trend towards the presentation of HuŶtiŶgtoŶ͛s in later life. Interestingly, the frequency of reduced 
penetrance alleles in the 50% at-risk group > 60 years old was 6.4% compared to 4.5% for all age 
groups at 50% risk.  
 
Of the predictive tests performed on participants with an apriori risk of 50%, 54.8% were gene-
negative whereas 44.6% were gene positive. The tendency to acquire slightly more normal results 
when the expected frequencies would be 50:50 is a phenomenon that is consistent with other 
studies (18, 20, 22, 24, 26). This may be explained by the fact that the 50% risk of developing 
HuŶtiŶgtoŶ͛s disease is the risk at birth and those who are asymptomatic in adult life when they 
present for testing have a slightly reduced risk by virtue of the fact that they have not developed 
symptoms thus far.  In keeping with this, we observed a lower frequency of abnormal results in the 
higher age groups (data not shown).  
 
Genotypes with intermediate alleles (IAs) and reduced penetrance (RP) alleles were recorded 
consistently from 2010 onwards with their observed frequencies in the 50% at-risk population being 
a minimum of 4.2% and 4.5%, respectively. Sequeiros et al assessed CAG repeat length in the general 
population in Portugal and determined the frequency of genotypes with intermediate alleles (IAs) 
and reduced penetrance (RP) alleles to be 6% and 0.1%, respectively (28). In Canada, the 
corresponding figures were 5.8% and 0.4%, respectively (29).The current study demonstrates a 
higher proportion of reduced penetrance alleles in the predictive testing population and is in 
keeping with Sequeiros͛ figure of 4.8% in the Portugese predictive testing population (28). 
Furthermore, the current study only reports on the largest allele size; therefore, it may 
underestimate the presence of an additional IA/RP allele in genotypes where a larger CAG expansion 
was present.   
 The participant-reported reasons for undergoing predictive testing were recorded for 4743 (50.4%) 
individuals. Decreasing uncertainty was the most commonly cited reason for having the predictive 
test with future and family planning also being important factors. It is important to note that whilst 
an abnormal predictive test informs the testee they will develop the disease, it does not predict the 
age of onset, thereby introducing a different type of uncertainty. Furthermore, a result 
demonstrating a reduced penetrance allele once more maintains a level of uncertainty. These 
reasons are similar to those given by participants when predictive testing was first introduced (30). 
One can anticipate that the development of effective disease-modifying therapies targeted at those 
in the pre-symptomatic phase of the disease would provide a major reason for at-risk individuals to 
undergo predictive testing.  
 
 
Limitations of the current study 
In the current study, basic information on participants undergoing predictive testing was collected 
annually from 23 centres over a 22 year period. Over the course of the study, some centres did not 
provide data for every year of predictive testing (overall, a maximum of 5.4% of yearly centre-level 
reports were missing; therefore, imputation of missing data was required to calculate more reliably 
an estimate of cumulative uptake of predictive testing. In some instances, there was incomplete or 
uninterpretable information on prior risk, gender and test results recorded on the database. A 
further issue is that the codes of practice were not standardised across the 23 centres and multiple 
laboratories; for example, in some centres, individuals who presented as being at risk may have had 
neurological signs of HD but still went through a predictive testing protocol rather than diagnostic 
testing.   
 
The Tassicker method for calculation of the cumulative uptake of testing relies on an accurate 
measure of prevalence for Huntington͛s disease in the adult population and the ratio of 
symptomatic cases:population at 50% risk (9). Based on highest quality and most current evidence 
we estimated these to be 12.3 per 100 000 adults and 1:4.2, respectively. The UK prevalence of HD is 
a contentious issue: two recent studies calculating prevalence figures based on two different GP 
research databases in the UK gave vastly different estimates of 5.96 (from The Health Network 
Improvement database) (12)  and 12.3 (from the General Practice Research Database) (13) per 
100,000 of the population. This significant discrepancy can be explained, in part, by the fact that the 
former study looked at the prevalence in the whole population whereas the latter exclusively looked 
at the population over 20 years old (14); the significance of this is that the prevalence of cases under 
the age of 20 years is lower. In the present study, the figure of 12.3 per 100 000 in the over-20 
population was used to calculate the cumulative uptake of predictive testing over the study period. 
The rationale for this is that, firstly, it is based on recent evidence and, secondly, the present study is 
principally interested in the prevalence in the adult population who can reliably give informed 
consent for predictive testing.  
 
If our parameter estimates are inaccurate, then the estimated cumulative uptake figure will vary. 
However, as the sensitivity analysis shows, regardless of the probable parameter estimates used, 
less than 27% of individuals of individuals at 50% risk of HD have taken the predictive test and our 
best estimate is that the cumulative uptake of predictive testing is approximately 17.4% (95% CI 
16.9% to 18.0%)  
 
Another limitation of the Tassicker method is the assumption of a constant disease duration 
throughout the course of the study. We used the average disease duration from symptom onset to 
death as being 18.8 years based on the average of two large cohort studies, however, it may be 
argued that the disease duration has increased over the last 22 years with the provision of the direct 
mutation test giving earlier diagnoses and minor improvements in survival due to medical, nursing 
and social care interventions.  
 
Conclusion 
The current study identifies that the vast majority of those at-risk of HD in the UK (more than 80%) 
have not participated in the predictive testing program. This is likely to be due to a combination of 
factors including the reluctance to undertake testing in the absence of disease-modifying or 
neuroprotective therapies and barriers to testing and accessing appropriate services. There are a 
number of clinical trials which are currently enrolling and ongoing (31).  If even a single study agent 
shows a neuroprotective effect in HuŶtiŶgtoŶ͛s disease, then an awareness of size of the at-risk 
population who have not yet had their gene status confirmed is necessary in order to optimally plan 
intervention in the pre-symptomatic phase of the illness.   
 
 
TABLES 
 
Table 1  
Demographic information and apriori risk  of participants undergoing predictive testing (1993-2014) 
Variable   
Gender  
  Male  4077 (43.3%) 
  Female 5122 (54.4%) 
  Missing information 208   (2.2%) 
  Total  9407 
  
Age  
  < 18 68     (0.8%) 
  18-30 2776 (29.5%) 
  31-40 2681 (28.5%) 
  41-50 2001 (21.3%) 
  51-60 1151 (12.2%) 
  > 60 586   (6.2%) 
  Missing information 144   (1.5%) 
  Total 9407 
  
Median age (IQR)  
  Male 37 years (29-47) 
  Female 37 years (29-48) 
  Overall  37 years (29-47) 
  
Apriori risk of Huntington’s disease   
  12.5% 13     (0.1%) 
  25% 642   (6.8%) 
  50% 8441 (89.7%) 
  Other/missing information 311   (3.3%) 
  Total 9407 
 
 
 
 
Table 2  
Results of predictive testing for individuals with an apriori risk of 50%  
Outcome   
1993-2014  
  Negative (<36 repeats) 4629 (54.8%) 
  Positive (≥ 36 repeats) 3790 (44.9%) 
  Result missing/uninterpretable 22     (0.3%) 
  Total  8441 
    
2010-2014  
  Normal (0-27 Repeats) 857   (46.9%) 
  Intermediate Alleles (28-35 repeats) 77     (4.2%)  
  Reduced Penetrance Alleles (36-39 repeats) 82     (4.5%) 
  Affected (40+ repeats)  812   (44.4%) 
  Total  1828 
  
 
 
Table 3 
Alternative calculated figures of of cumulative uptake of predictive testing based on alternative 
parameter estimates 
UK Prevalence of HD 
(per 100 000 adult 
population) 
Ratio of symptomatic individuals to 
individuals at 50% risk of 
developing HD. 
Calculated Cumulative 
Uptake (95% CI) (%)  
8 1:4.2 26.8 (25.9 – 27.6) 
8 1:5 22.3 (21.6 – 23.0) 
   
10 1:4.2 21.4 (20.7 – 22.1) 
10 1:5 17.8 (17.3 – 18.4) 
   
12 1:4.2 17.8 (17.3 – 18.4) 
12 1:5 14.9 (14.4 – 15.3) 
   
12.3 1:4.2 17.4 (16.9 – 18.0) 
12.3 1:5 14.5 (14.0 – 15.0) 
   
13 1:4.2 16.5 (16.0 – 17.0) 
13 1:5 13.7 (13.3 – 14.2) 
 
 
 
 
 
 
 
Table 4  
Studies of Uptake of Predictive Testing in Huntington's disease 
 
Population Study Period Reported HD 
Prevalence 
(per 100 000) 
Number of 
Completed 
Tests 
Use of the 
Tassicker 
Formula  
Reported 
Uptake (%) 
Authors
EUROPE 
      
France 1993-1999 5 409 No 5 Goizet et
Greece 1995-2008 5.4 256 No 8.6 Panas et
Netherlands 1987-1997 6.5 752 No 24 Maat-Ki
North-Rhine Westfalia, Germany 1993-2004 10 248 No - Bernhar
Northern Ireland 1990-2009  10.6 212 Yes 14.4-14.6  Morriso
Slovenia 1997-2007 5.16 68 No 44.7 Peterlin
United Kingdom 1987-1997 7.5 2722 No 18 Harper et
       
NORTH AMERICA 
      
Canada 1987-2000 8.4 1061 No 18 Creighto
Montreal, Canada 1994-2008 - 135 No 9.2 Dufrasn
       
AUSTRALIA 
      
Victoria, Australia 1996-2003 8 333 Yes 15.4 Tassicke
 
 
 
 Table 5 
Sources of variation in estimated cumulative uptake of predictive testing in different studies 
Sources of Variation 
  
Potential overestimation Inclusion of tests performed on those with apriori risk of 25% in 
the numerator but not the denominator. [Maat-Kievit et al] 
 
 No adjustment for the increasing number of at-risk individuals 
over the study period [Goizet et al, Panas et al, Bernhardt et al, 
Harper et al, Creighton et al, Dufrasne et al] 
 Expressing uptake as the fraction of tests performed in 
individuals who engaged in the counselling process rather than 
the estimated at-risk population [Bernhardt et al] 
 Expressing uptake as a fraction of tests done in individuals 
registered being at-risk on HD registries rather than the 
estimated, total at-risk population. [Maat-Kieivit et al] 
 Use of the Conneally ratio of symptomatic individuals: 50% at 
risk individuals as being 1:5 on theoretical grounds which may 
overestimate the at-risk population when compared to the ratio 
of 1:4.2 given found empirically. [Creighton et al, Panas et al]  
 Underascertainment of HD cases may underestimate disease 
prevalence and thereby underestimate the population at 50% 
risk.  
  
Potential underestimation Inclusion of individuals under 18 in the at-risk population who 
generally unable to access predictive testing. Those under 18 
may represent 5.6-9% of the 50% at-risk population. [Harper et 
al, Creighton et al,  Panas et al] 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9407 Predictive Tests performed in 23 UK Centres 
from 1993-2014 
8441 Predictive Tests performed on participants with 
an apriori risk of 50% 
966 tests performed on 
individuals with an apriori risk 
other than 50% were excluded 
8288 Predictive Tests performed on participants aged 
≥ 18 and with an apriori risk of 50%  
153 tests where the age of the 
participant was < 18 or the age 
was missing from the dataset 
were excluded 
Figure 1 
Selection of Cases for Analysis of Cumulative Uptake  
8093 Predictive Tests performed on participants aged 
≥ 18 and with an apriori risk of 50%  
from 1994-2014 
195 tests performed in 1993, 
when predictive testing was only 
available for part of the year, 
were excluded 
  
 
 
 
 
 
 
 
 
 
 
Figure 2 
Cumulative Uptake of Predictive Testing for HD in the 50% at-risk population assuming different 
prevalence estimated for HD in the UK adult population (shaded bars represent 95% confidence 
intervals).   
 
Imputation of minimal 
missing data: 
349 (SD 34.1) 
participants. 
8442 Predictive Tests performed on participants aged 
≥ 18 and with an apriori risk of 50%  
from 1994-2014 after imputation of missing data 
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